{"groups":[{"description":"Participants received high dose LY3499446 as oral monotherapy twice daily (BID) in 21-day cycles.","id":"FG000","title":"LY3499446 Phase 1 Cohort A1 (High Dose)"},{"description":"Participant received mid dose LY3499446 as oral monotherapy once every other day (QOD) in 21-day cycles.","id":"FG001","title":"LY3499446 Phase 1 Cohort AO (Mid Dose)"},{"description":"Participants received low dose LY 3499446 as oral monotherapy once daily (QD) in 21-day cycles.","id":"FG002","title":"LY3499446 Phase 1 Cohort A-2 (Low Dose)"},{"description":"LY3499446 combined with either abemaciclib (orally), erlotinib (orally), or cetuximab (IV).\n\nThe trial was terminated prior to initiation of this portion.","id":"FG003","title":"LY3499446 + Combination Drug Phase 1"},{"description":"LY3499446 monotherapy orally. LY3499446 combined with either abemaciclib (orally), erlotinib (orally), or cetuximab (IV).\n\nThe trial was terminated prior to initiation of this portion.","id":"FG004","title":"LY3499446 Monotherapy + Combination Drug Phase 2"},{"description":"Docetaxel IV infusion.\n\nThe trial was terminated prior to initiation of this portion.","id":"FG005","title":"Docetaxel Phase 2"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"}],"type":"Received at Least One Dose of Study Drug"},{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"A participant was identified as having completed the study if the participant was observed until event of progressive disease (PD) or death, or the participant had discontinued study treatment and is in follow up at the time of the final analysis.\n\nThe study was terminated due to an unexpected toxicity finding."}